The complement system in the airway epithelium: An overlooked host defense mechanism and therapeutic target? - 04/05/18
Doi : 10.1016/j.jaci.2017.11.046
Hrishikesh S. Kulkarni, MD, MSCI a, b, M. Kathryn Liszewski b, Steven L. Brody, MD a, John P. Atkinson, MD b, ⁎ 
a Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University in St Louis, St Louis, Mo
b Division of Rheumatology, Department of Medicine, Washington University in St Louis, St Louis, Mo
∗Corresponding author: John P. Atkinson, MD, Washington University School of Medicine, Department of Medicine, Division of Rheumatology, 660 South Euclid Ave, Campus Box 8045, St Louis, MO 63110.Washington University School of MedicineDepartment of MedicineDivision of Rheumatology660 South Euclid AveCampus Box 8045St LouisMO63110
Key words : Complement, allergic rhinitis, properdin, epithelial cells, asthma, ovalbumin, cystic fibrosis, bronchiolitis, pulmonary fibrosis, anaphylatoxins
Le texte complet de cet article est disponible en PDF.
Plan
| Supported by the National Institutes of Health (NIH; R01 GM0099111 to J.P.A. and R01HL122585 to S.L.B.) and NIH training grants in the Principles of Pulmonary Research (5T32 HL007317 to H.S.K., and the Immunobiology of Rheumatic Diseases (5T32-AR007279 to H.S.K.). Research reported in this publication is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the NIH (P30AR048335); an NIH grant for the Washington University Institute of Clinical and Translational Sciences (3UL1 TR000448); and the Hubert C. and Dorothy R. Moog Professorship (to S.L.B.) supported by the Barnes-Jewish Hospital Foundation. |
|
| Disclosure of potential conflict of interest: J. P. Atkinson has received grants from the National Institutes of Health (2 R01 GM099111 and R21 AR069833) and the Rheumatology Research Foundation; has board memberships with Compliment Corporation, Kypha Inc, and Gemini Therapeutics; has consultant arrangements with Achillion Pharmaceuticals, BioMarin Pharmaceuticals, Annexon Biosciences, Celldex Therapeutics, Clinical Pharmacy Services CDMI, Kypha Inc, Omeros Corporation, and True North Therapeutics; and receives stock/stock options from Compliment Corporation, Kypha Inc, and Gemini Therapeutics. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 5
P. 1582 - mai 2018 Retour au numéro
Article précédent
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines
- Taylor A. Doherty, David H. Broide
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?